GENNIEFY
Market News
Latest financial news and analysis from global markets
MSFT
Nvidia’s $5.7 Trillion Market Cap Faces Its Toughest Test Yet. Can It Beat 75% Gross Margin Expectations Before Earnings?
NVIDIA (NASDAQ:NVDA) reports fiscal Q1 2027 results later today, and the bar has rarely looked higher. The traders on CNBC’s Fast Money segment “Yields Surge and Prepping for Nvidia Results” framed it around a single number: “Anything south of 75% gross margins, then we can start having a different conversation. 75% is a bogey.” The ... Nvidia’s $5.7 Trillion Market Cap Faces Its Toughest Test Yet. Can It Beat 75% Gross Margin Expectations Before Earnings?
TGT
Target posts Q1 2026 earnings beat: Sales surge, outlook raised
Net sales rose 6.7% in the first quarter, with comparable sales up 5.6% — the retailer's first positive comp in five quarters
INTC
Berkshire Hathaway Just Dumped a Beloved Stock. Here's What It's Buying Instead.
Berkshire Hathaway sold its Amazon shares and bought Macy's stock.
AMZN
Berkshire Hathaway Just Dumped a Beloved Stock. Here's What It's Buying Instead.
Berkshire Hathaway sold its Amazon shares and bought Macy's stock.
INTC
Intel, Micron, and other semiconductor stocks extend bounce ahead of Nvidia earnings
Chip stocks bounce ahead of Nvidia eaernings.
AMD
Intel, Micron, and other semiconductor stocks extend bounce ahead of Nvidia earnings
Chip stocks bounce ahead of Nvidia eaernings.
NVDA
Intel, Micron, and other semiconductor stocks extend bounce ahead of Nvidia earnings
Chip stocks bounce ahead of Nvidia eaernings.
GILD
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 10 Best Long Term Low Risk Stocks to Buy According to Hedge Funds. On May 10, Morgan Stanley lowered its price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $168 from $175. It reiterated an Overweight rating on the shares. The firm updated its model for the company […]
BMY
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its use in research, drug development, manufacturing and other commercial and medical affairs. • Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.
WMT
Target Rises In Buy Zone On Beat-And-Raise Report. Walmart Earnings Due.
High gas prices are hitting retailers. But Target beat and guided up as a transformation takes hold. A digital expansion is fueling Walmart earnings.
TGT
Target Rises In Buy Zone On Beat-And-Raise Report. Walmart Earnings Due.
High gas prices are hitting retailers. But Target beat and guided up as a transformation takes hold. A digital expansion is fueling Walmart earnings.
MS
Morgan Stanley gives Hong Kong bankers restricted devices for China travel
Five people familiar with the matter told the FT the devices have “limited functionality”, with access only to “work emails and online meeting apps”.